Page 92 - 80_01

Jorge
Enrique
Machado-­-Alba

94.
Nahta
R.
Molecular
Mechanisms
of
Trastuzumab-­-Based
Treatment
in
HER2-­-
Overexpressing
Breast
Cancer.
ISRN
Oncol
2012,
428062
(2012).

95.
Gunturu
KS,
Woo
Y,
Beaubier
N,
Remotti
HE,
Saif
MW.
Gastric
cancer
and
trastuzumab:
first

biologic
therapy
in
gastric
cancer.
Ther
Adv
Med
Oncol
5(2),
143-­-51
(2013).

96.
Qin
T,
Yuan
Z,
Peng
R,
Bai
B,
Shi
Y,
Teng
X,
et
al.
HER2-­-positive
breast
cancer
patients

receiving
trastuzumab
treatment
obtain
prognosis
comparable
with
that
of
HER2-­-negative

breast
cancer
patients.
Onco
Targets
Ther
6,
341-­-7
(2013).

97.
Stebbing
J,
Payne
R,
Reise
J,
Frampton
AE,
Avery
M,
et
al.
The
Efficacy
of
Lapatinib
in

Metastatic
Breast
Cancer
with
HER2
Non-­-Amplified
Primary
Tumors
and
EGFR
Positive

Circulating
Tumor
Cells:
A
Proof-­-Of-­-Concept
Study.
PLoS
ONE
8(5),
e62543
(2013).

98.
Diessner
J,
Bruttel
V,
Becker
K,
Pawlik
M,
Stein
R,
Häusler
S,
et
al.
Targeting
breast
cancer

stem
cells
with
HER2-­-specific
antibodies
and
natural
killer
cells.
Am
J
Cancer
Res
3(2),

211-­-20
(2013).

99.
Tinoco
G,
Warsch
S,
Glück
S,
Avancha
K,
Montero
AJ.
Treating
breast
cancer
in
the
21st

century:
emerging
biological
therapies.
J
Cancer
4(2),
117-­-32
(2013).

100.
Chen
F-­-T,
Yang
C-­-M,
Yang
C-­-H.
The
Protective
Effects
of
the
Proteasome
Inhibitor

Bortezomib
(Velcade)
on
Ischemia-­-Reperfusion
Injury
in
the
Rat
Retina.
PLoS
ONE
8(5),

e64262
(2013).

101.
Vacchelli
E,
Eggermont
A,
Galon
J,
Sautès-­-Fridman
C,
Zitvogel
L,
Kroemer
G,
et
al.
Trial

watch:
Monoclonal
antibodies
in
cancer
therapy.
Oncoimmunology
2(1),
e22789
(2013).

102.
Machado
J,
Moncada
JC,
Pineda
R.
[Profile
of
use
of
anti
tumor
necrosis
factor
in

Colombian
patients].
Biomedica
31(2),
250-­-7
(2011).

103.
Machado
Alba
JE,
Moncada
Escobar
JC.
[Evolution
of
consumption
of
high-­-cost
drugs
in

Colombia].
Rev
Panam
Salud
Publica
31(4),
283-­-9
(2012).

90